Post-Traumatic Stress Disorder
A debilitating mental health condition triggered by experiencing or witnessing a terrifying event, causing flashbacks, nightmares, and severe anxiety.
Emergency Management: Acute suicidal or homicidal behavior necessitating involuntary psychiatric hospitalization. Severe dissociative states where the patient loses touch with reality.
Post-Traumatic Stress Disorder (PTSD) is a severe, chronic psychiatric disorder that develops in some individuals after exposure to a terrifying event or ordeal in which grave physical harm occurred or was threatened. It is characterized by intrusive memories, avoidance of trauma-related stimuli, negative alterations in mood and cognition, and marked hyperarousal.
Detailed Overview
While most people experience stress reactions following trauma, PTSD is diagnosed when these symptoms persist beyond one month and cause significant functional impairment. The trauma can be a single event (e.g., car accident, assault, natural disaster) or complex, prolonged exposure (e.g., childhood abuse, combat). The condition fundamentally alters the brain's fear-processing network, causing the individual to perceive current safety through the lens of past trauma. Patients frequently suffer from severe sleep disturbances, dissociation, and crippling survivor's guilt, heavily impacting their interpersonal relationships and ability to work.
Epidemiology & Demographics
Lifetime prevalence in the US is approximately 6-8%. Women are twice as likely as men to develop PTSD, largely due to higher rates of exposure to sexual assault and interpersonal violence. Prevalence among combat veterans is heavily elevated (up to 15-30%).
Etiological Mechanism
Requires a precipitating traumatic event (Criterion A: exposure to actual or threatened death, serious injury, or sexual violence). However, exposure alone is not sufficient; genetic, neurobiological, and psychosocial vulnerabilities interact to prevent the normal extinction of the fear memory.
Primary Causes
Triggered by trauma. The failure of the brain to properly consolidate and extinguish the memory of the traumatic event, leading to the memory being stored as a present, ongoing threat rather than a past narrative.
PTSD is characterized by a hyperactive amygdala (exaggerated fear response) and a hypoactive medial prefrontal cortex (mPFC). Normally, the mPFC exerts inhibitory control over the amygdala to extinguish fear when a threat has passed; in PTSD, this top-down inhibition fails. Additionally, the hippocampus (responsible for contextualizing memories in time and space) is often reduced in volume and function. This causes traumatic memories to be experienced as fragmented, visceral flashbacks that feel like they are happening 'now' rather than 'then'. The hypothalamic-pituitary-adrenal (HPA) axis is also dysregulated, with chronically low baseline cortisol but hypersensitive glucocorticoid receptors, locking the body in a state of high sympathetic arousal.
Diagnostic Criteria & Guidelines
DSM-5 criteria require exposure to a traumatic event, followed by symptoms from 4 clusters lasting >1 month: 1) Intrusion (≥1 symptom), 2) Avoidance (≥1 symptom), 3) Negative alterations in cognitions and mood (≥2 symptoms), 4) Alterations in arousal and reactivity (≥2 symptoms). Symptoms must cause clinically significant distress or impairment.
Trauma-focused psychotherapy is the most effective intervention. Gold standards include Prolonged Exposure (PE) therapy, Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR). First-line pharmacotherapy includes SSRIs (Sertraline 50-200 mg/day or Paroxetine 20-60 mg/day) or SNRIs (Venlafaxine XR 75-225 mg/day) to reduce core symptoms and comorbid depression.
Second-Line & Adjunctive Therapy
If SSRIs fail, Mirtazapine or Tricyclic Antidepressants (Amitriptyline). For severe, treatment-resistant PTSD, off-label use of atypical antipsychotics (Quetiapine, Risperidone) as adjuncts. Prazosin (an alpha-1 blocker, 1-15 mg at bedtime) is frequently used specifically to suppress trauma-related nightmares, though recent large trials have shown mixed results.
Surgical & Procedural Management
None.
Patient Counseling & Advice
Validate the patient's experience; explain that their symptoms are a normal biological reaction to an abnormal event, not a sign of weakness. Emphasize that avoidance, while protective in the short term, fuels the disorder long-term. Prepare them that trauma-focused therapy is hard work and may temporarily increase anxiety before it gets better. Warn against the use of benzodiazepines, as they interfere with the fear extinction process required for therapy to work.
Follow-Up & Monitoring Schedule
Weekly or biweekly during active psychotherapy. Monitor heavily for signs of worsening depression, emergence of substance abuse, and suicidal ideation. Use the PTSD Checklist for DSM-5 (PCL-5) to track symptom severity over time.
Preventive Strategies
Providing rapid psychological first aid, ensuring safety, and fostering social support immediately after a trauma reduces PTSD risk. Routine debriefing (forcing people to recount the trauma immediately) is NOT recommended and may increase risk.
Highly variable. With evidence-based trauma-focused therapy, up to 50-60% of patients achieve remission. However, roughly one-third develop chronic, unremitting symptoms requiring lifelong management.